

Datasheet: HCA301P BATCH NUMBER 158812

Description:	HUMAN ANTI NIVOLUMAB:HRP		
Specificity:	NIVOLUMAB		
Other names:	Opdivo		
Format:	HRP		
Product Type:	Monoclonal Antibody		
Clone:	AbD30258_hlgG1		
Isotype:	lgG1		
Quantity:	0.1 mg		

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	•			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is conjugated to horseradish peroxidase (HRP) and supplied as liquid.

Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	Antibody concentration 0.1 mg/ml
Immunogen	Nivolumab

Specificity

Human Anti-Nivolumab Antibody, clone AbD30258_hlgG1 is a paratope specific, inhibitory anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug nivolumab. The antibody does not recognize recombinant human programmed cell death 1 (PD-1) or nivolumab in complex with recombinant human PD-1 and can be used to measure free nivolumab levels in serum from patients.

Clone AbD30258_hlgG1 is a fully human recombinant monoclonal antibody with lgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. A pair of anti-nivolumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in full immunoglobulin format, is recommended as the detection antibody paired with clone AbD30255 (HCA299) in monovalent Fab format as the capture antibody.

Nivolumab (Opdivo) is a fully human antibody (IgG4/kappa), with the heavy chain mutation S228P (IgG4-Pro). It is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF. It is also approved for treatment of advanced non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin's lymphoma and advanced head and neck squamous cell carcinoma. Nivolumab is a checkpoint inhibitor and acts as an immuno-modulator by blocking ligand activation of PD-1 receptor on T cells, thereby activating T cells to attack the cancer. Nivolumab blocks PD-1 interaction with PD-1 ligand (PD-L1) and PD-1 ligand 2 (PD-L2).

View a summary of all anti-nivolumab antibodies

Affinity The monovalent intrinsic affinity of AbD30258_hlgG1 was measured as K_D = 2 nM by real time, label free molecular interaction analysis on immobilized nivolumab. ELISA Clone AbD30258_hlgG1 can be used in a direct ELISA or as detection antibody for nivolumab in a bridging ELISA together with HCA299 as the capture reagent.

Protocol: PK bridging ELISA to measure free drug

Storage This product is shipped frozen.

When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.

Guarantee 12 months from date of despatch

Acknowledgements Sold under license of U.S. Patents 7785859 and 8273688 and corresponding patents.

This antibody was developed by Bio-Rad.

Opdivo is a trademark of Bristol-Myers Squibb Company.

Health And Safety
Information

Material Safety Datasheet documentation #10094 available at:

https://www.bio-rad-antibodies.com/SDS/HCA301P
10094

For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory

For research purposes only

Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Negative Controls

RECOMBINANT HUMAN IgG1 LAMBDA ALLOTYPE G1m3 (HCA049)

Recommended Useful Reagents

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)
HISPEC ASSAY DILUENT (BUF049A)
HUMAN ANTI NIVOLUMAB (HCA299)

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M386809:210528'

Printed on 29 Aug 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint